Pragmatic Clinical Trial Resources-Lessons from other Networks/Situations: How long is long enough?

Lessons from other Networks/Situations: How long is long enough?

Video Transcription

Video Summary

The speaker describes a GCIG global study on exceptional responders to PARP inhibitors in platinum-sensitive recurrent ovarian cancer. The project asks whether long-term responders are effectively cured, whether PARP inhibitors should be continued indefinitely, and the long-term risk of MDS/AML. It combines an international clinician survey and a retrospective cohort of de-identified patient data. The speaker highlights major governance, ethics, IT, and data-transfer challenges across countries, but notes successful data lock from 37 sites in 14 countries. The talk ends with lessons on harmonized agreements, early regulatory engagement, IT support, and fair collaborator recognition.

Asset Subtitle

How long is long enough? by Yeh Chen Lee

Keywords

PARP inhibitors

ovarian cancer

exceptional responders

MDS AML risk

international study